Literature DB >> 25064228

Histological features of primary tumors after induction or high-dose chemotherapy in high-risk neuroblastoma.

Tomoro Hishiki1, Hiroshi Horie, Yasuyuki Higashimoto, Katsumi Yotsumoto, Shugo Komatsu, Yuri Okimoto, Harumi Kakuda, Yuichi Taneyama, Takeshi Saito, Keita Terui, Tetsuya Mitsunaga, Mitsuyuki Nakata, Hidemasa Ochiai, Moeko Hino, Kumiko Ando, Hideo Yoshida, Jun Iwai.   

Abstract

PURPOSE: In the recent years in Japan, an increasing number of patients with neuroblastoma (NB) are being treated by the "delayed local treatment (DL)" policy, undergoing surgery after the completion of high-dose chemotherapy with hematopoietic stem cell rescue (HDC). We reviewed the histopathological findings of second-look operations, including those of patients treated with DL. PATIENTS: From 1998 to 2013, 26 patients with high-risk NB underwent radical operation following chemotherapy. Surgery was performed after induction chemotherapy in 17 cases (standard; STD), whereas 9 cases completed induction chemotherapy and HDC before undergoing tumor resection (DL). The amount of necrosis and the degree of differentiation within the post-treatment tumor were assessed.
RESULTS: Eighty-eight percent of the tumors showed necrosis in more than 1/3 of the specimen. Two DL cases showed complete disappearance of viable tumor cells. Amount of necrosis did not affect the prognosis of the patient. Tumors with immature, poorly differentiated phenotypes showed an extremely aggressive thereafter. Though not statistically proven, (123)I-MIBG (metaiodobenzylguanidine) uptake may be correlated with the amount of viable cells remaining within the tumor, but not with the degree of differentiation.
CONCLUSIONS: Our results support the previous reports advocating that tumors that sustain unfavorable histology after chemotherapy behave aggressively thereafter.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25064228     DOI: 10.1007/s00383-014-3564-0

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN: 0179-0358            Impact factor:   1.827


  22 in total

1.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols.

Authors:  Stefan S Bielack; Beate Kempf-Bielack; Günter Delling; G Ulrich Exner; Silke Flege; Knut Helmke; Rainer Kotz; Mechthild Salzer-Kuntschik; Matthias Werner; Winfried Winkelmann; Andreas Zoubek; Heribert Jürgens; Kurt Winkler
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

2.  Histologic survey of neuroblastomas after intensive induction chemotherapy.

Authors:  Yoshiaki Tsuchida; Jun Miyauchi; Minoru Kuroiwa; Norio Suzuki; Jun Sakamoto; Makoto Suzuki; Toshiji Shitara
Journal:  Pediatr Blood Cancer       Date:  2005-10-15       Impact factor: 3.167

3.  Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee.

Authors:  H Shimada; I M Ambros; L P Dehner; J Hata; V V Joshi; B Roald
Journal:  Cancer       Date:  1999-07-15       Impact factor: 6.860

4.  Complete necrosis induced by preoperative chemotherapy in Wilms tumor as an indicator of low risk: report of the international society of paediatric oncology (SIOP) nephroblastoma trial and study 9.

Authors:  L Boccon-Gibod; A Rey; B Sandstedt; J Delemarre; D Harms; G Vujanic; J De Kraker; A Weirich; M F Tournade
Journal:  Med Pediatr Oncol       Date:  2000-03

5.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.

Authors:  G M Brodeur; R C Seeger; M Schwab; H E Varmus; J M Bishop
Journal:  Science       Date:  1984-06-08       Impact factor: 47.728

Review 6.  Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

Authors:  G M Brodeur; J Pritchard; F Berthold; N L Carlsen; V Castel; R P Castelberry; B De Bernardi; A E Evans; M Favrot; F Hedborg
Journal:  J Clin Oncol       Date:  1993-08       Impact factor: 44.544

7.  Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities.

Authors:  P Picci; B T Rougraff; G Bacci; J R Neff; L Sangiorgi; A Cazzola; N Baldini; S Ferrari; M Mercuri; P Ruggieri
Journal:  J Clin Oncol       Date:  1993-09       Impact factor: 44.544

8.  Prognostic factor in neuroblastoma.

Authors:  A E Evans; G J D'Angio; K Propert; J Anderson; H W Hann
Journal:  Cancer       Date:  1987-06-01       Impact factor: 6.860

9.  Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.

Authors:  Susan G Kreissman; Robert C Seeger; Katherine K Matthay; Wendy B London; Richard Sposto; Stephan A Grupp; Daphne A Haas-Kogan; Michael P Laquaglia; Alice L Yu; Lisa Diller; Allen Buxton; Julie R Park; Susan L Cohn; John M Maris; C Patrick Reynolds; Judith G Villablanca
Journal:  Lancet Oncol       Date:  2013-07-25       Impact factor: 41.316

10.  Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular.

Authors:  Michel Peuchmaur; Emanuele S G d'Amore; Vijay V Joshi; Jun-ichi Hata; Borghild Roald; Louis P Dehner; Robert B Gerbing; Daniel O Stram; John N Lukens; Katherine K Matthay; Hiroyuki Shimada
Journal:  Cancer       Date:  2003-11-15       Impact factor: 6.860

View more
  2 in total

Review 1.  Nanotechnology-Based Diagnostic and Therapeutic Strategies for Neuroblastoma.

Authors:  Hui Yan; Bo Zhai; Fang Yang; Zhenliang Chen; Qiang Zhou; Ana Cláudia Paiva-Santos; Ziqiao Yuan; Yang Zhou
Journal:  Front Pharmacol       Date:  2022-06-02       Impact factor: 5.988

2.  Comparison Between Diffusion-Weighted MRI and 123 I-mIBG Uptake in Primary High-Risk Neuroblastoma.

Authors:  Laura Privitera; Patrick W Hales; Layla Musleh; Elizabeth Morris; Natalie Sizer; Giuseppe Barone; Paul Humphries; Kate Cross; Lorenzo Biassoni; Stefano Giuliani
Journal:  J Magn Reson Imaging       Date:  2020-12-06       Impact factor: 5.119

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.